Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer

Abstract

ObjectivesAnaplastic thyroid cancer (ATC) cells cannot retain the radionuclide iodine 131 (131I) for treatment due to the inability to uptake iodine. This study investigated the feasibility of combining radionuclides with photothermal agents in the diagnosis and treatment of ATC.Methods131I was labeled on human serum albumin (HSA) by the standard chloramine T method. 131I-HSA and indocyanine green (ICG) were non-covalently bound by a simple stirring to obtain 131I-HSA-ICG nanoparticles. Characterizations were performed in vitro. The cytotoxicity and imaging ability were investigated by cell/in vivo experiments. The radio-photothermal therapy efficacy of the nanoparticles was evaluated at the cellular and in vivo levels.ResultsThe synthesized nanoparticles had a suitable size (25–45 nm) and objective biosafety. Under the irradiation of near-IR light, the photothermal conversion efficiency of the nanoparticles could reach 24.25%. In vivo fluorescence imaging and single-photon emission CT (SPECT)/CT imaging in small animals confirmed that I-HSA-ICG/131I-HSA-ICG nanoparticles could stay in tumor tissues for 4–6 days. Compared with other control groups, 131I-HSA-ICG nanoparticles had the most significant ablation effect on tumor cells under the irradiation of an 808-nm laser.ConclusionsIn summary, 131I-HSA-ICG nanoparticles could successfully perform dual-modality imaging and treatment of ATC, which provides a new direction for the future treatment of iodine-refractory thyroid cancer.

Nanomaterials: a promising multimodal theranostics platform for thyroid cancer

“…In vivo fluorescence imaging and single-photon emission computed tomography (SPECT) imaging in mice confirmed that I-HSA-ICG/ 131 I-HSA-ICG nanoparticles can remain in tumor tissues for 4-6 days, resulting in the most significant ablation effect on tumor cells under 808 nm laser irradiation. 171 In conclusion, nanomaterials offer a promising approach for combining PTT and radiotherapy. The use of PDA nanoparticles and HSA-ICG/ 131 I-HSA-ICG nanoparticles has shown significant inhibition and killing effects on anaplastic thyroid carcinoma (ATC) cells, with further inhibition of cell proliferation when combined with laser irradiation.…”

“…In vivo fluorescence imaging and single-photon emission computed tomography (SPECT) imaging in mice confirmed that I-HSA-ICG/ 131 I-HSA-ICG nanoparticles can remain in tumor tissues for 4–6 days, resulting in the most significant ablation effect on tumor cells under 808 nm laser irradiation. 171…”

Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas

“…Because of the adjustable composition and structure of nanoparticles, a nanoparticle system can be composed of different therapeutic strategies and imaging methods to achieve the synergistic anti-cancer treatment. 109 Zhang et al 40 constructed 131 I-HSA-ICG nanoparticles with 131 I labeled on human serum albumin (HSA) and indocyanine green (ICG) covalently bound to 131 I-HSA. The photothermal conversion efficiency of 131 I-HSA-ICG nanoparticles yields 24.25%, and they have the highest ablation effect on tumor cells under the irradiation of an 808-nm laser (2.5 W/cm 2 ) compared with that of other groups.…”

“… 37 BSA and hyaluronic acid (HA) loading remarkably enhances the targeting of drugs and their therapeutic efficacy. Sorafenib, 38 anti-VEGFR2 antibody, 39 indocyanine green, 40 and copper sulfide 41 loaded in mesoporous silica nanoparticles (MSNPs) coated with BSA present excellent outcomes in the treatment of targeted therapy, phototherapy and EBRT.…”

“… [ 39 ] Nanomaterials for improving the outcome of chemotherapy TSH-SiO 2 @Dox nanoparticles 35 Increasing the apoptotic rate in FTC-133 and TPC1 thyroid cells. [ 40 ] BSA-Dox-MONPs 224.3±21.2 −21.70±0.81 Increasing drug uptake; Inhibiting drug efflux. [ 41 ] Surfactant-coated doxorubicin-loaded PLGA nanoparticles 468±19 −11.2 Enable delivery of doxorubicin across the blood–brain barrier.…”